Anemia Clinical Trial
Verified date | November 2012 |
Source | Swiss Federal Institute of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
Iron deficiency (ID) is still a main public health problem in sub-Saharan Africa. Iron
deficient children have an increased risk for anemia which is associated with adverse infant
development that might be partly irreversible. In sub-Saharan Africa, the etiology of ID in
children is multifactoral; but the major causes are low iron dietary bioavailability and
intake from monotonous cereal-based complementary foods. Children < 5 years old can benefit
from iron-fortified complementary foods; however, these fortified complementary foods are
often not adapted to the requirements of children in specific setting. The investigators
developed a complementary food fortificant (CFF) which is added to local porridge and is
deemed to meet the nutrient intake requirement for iron in children 1-3 years of age. The
CFF is lipid-based and can therefore, if regularly used, increase the daily energy intake of
children which is often too low in developing countries with cereal-based diets.
The iron absorption from the mixture of CFF and porridge has to be optimized because it
contains quite a high amount of phytate, a well-known inhibitor of iron absorption. To
optimize iron absorption the investigators are planning three iron absorption studies using
different compounds of iron (FeSO4 + NaFeEDTA), additional vitamin C and phytase, which is
able to degrade phytate. In the first study, iron absorption will be determined from a
mixture of CFF and porridge fortified with 1) 6 mg FeSO4 and 2) 6 mg FeSO4 plus additional
vitamin C. In the second study, the test meals will be fortified with 1) 6 mg FeSO4 and 2) a
mixture of 3 mg FeSO4 + 3 mg NaFeEDTA. In the third study, test meals will be fortified with
1) 6 mg FeSO4, 2) 6 mg FeSO4 plus phytase, and 3) 6 mg FeSO4 plus additional vitamin C and
phytase. Iron absorption will be determined by incorporation of labeled iron into
erythrocytes, 14 days after the administration of a test meal containing labeled iron
(stable isotope technique). Sixty apparently healthy Beninese children 12-36 months of age
with a body weight > 8.3 kg will be included in the study. Additionally, the investigators
will test acceptability of CFFs based on different composition formulas by interviewing the
parents/legal guardians of the children after feeding the CFF for a defined period.
The results of these studies will provide important insights to optimize the iron absorption
of young children from a CFF mixed with local traditional porridge in developing countries.
Furthermore the studies will provide information on the acceptability of CFFs in such a
setting.
Status | Completed |
Enrollment | 60 |
Est. completion date | September 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Months to 36 Months |
Eligibility |
Inclusion Criteria: - Female or male children, 12 - 36 months of age - A body weight of at least 8.3 kg; weight for age = -3 Z-score - No malaria parasites in the blood smear + negative malaria rapid test - No hematuria - No intake of mineral/vitamin supplements 2 weeks before and during the study - No metabolic or gastrointestinal disorders Exclusion Criteria: - Fever (body temperature > 37.5 °C) - Severe anemia (hemoglobin < 8.0 g/dl) - Regular intake of medication - Blood transfusion or significant blood loss (accident, surgery) over the past 4 months - Currently participating in another clinical trial or having participated in another clinical trial during the last 3 months prior to the beginning of this study - Former participation in a study involving administration of iron stable isotopes - Subject who cannot be expected to comply with study protocol - Eating disorders or food allergy |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Benin | University of Abomey-Calavi | Cotonou |
Lead Sponsor | Collaborator |
---|---|
Swiss Federal Institute of Technology | Université d'Abomey-Calavi |
Benin,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Iron isotope ratio in blood samples | Whole blood samples will be collected to measure the shift in iron isotope ratios 16 days after administration of isotopic label in the first test meal. First test meal on study day 1, Second test meal on study day 2, Third (last) test meal on study day 3, Measurement of iron isotopic shift in blood samples collected on study day 17 |
Study day 17 (16 days after administration of isotopic label in the first test meal/End of the study) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |